Search results
Results from the WOW.Com Content Network
LARS ligaments demonstrate higher stability and lower morbidity rate compared to autograft in short-term research and in a 9-year study, LARS ligament showed a 100% survival rate. [5] Synthetic ACL grafts always develop creep, fatigue and failure so the demand for synthetic grafts with sufficient supply, satisfactory mechanical properties, and ...
However, systematic reviews of the LARS in regarding graft stability and long term functional outcomes, have highlighted several important gaps in existing literature that requires future investigation. The necessity of rehabilitation following LARS is well recognized, but there is limited evidence available that guide rehabilitation protocols ...
Graft (stylised as GRAFT) is a design studio conceived as a ‘label’ for architecture, urban planning, exhibition design, music and the “pursuit of happiness”. Graft was founded in 1998 in Los Angeles, California by Lars Krückeberg, Wolfram Putz and Thomas Willemeit, and headed by partner Alejandra Lillo from 2007 [1] until early 2011.
Shire engendered some high expectations after the Irish biopharmaceutical giant acquired San Diego's Advanced BioHealing in 2011 for $750 million. Over the next year or so, Shire formed a new San ...
BoneSupport AB is a Swedish biotech company active at the Ideon Science Park in the university town of Lund in Skåne, Sweden, founded in 1999 by Lars Lidgren, Professor of Orthopedic Surgery and Academic Head of Department at Lund University Hospital in Sweden which is a member of the ISOC group of orthopaedic centers.
Complex Post-Traumatic Stress Disorder (CPTSD) Complex PTSD is a form of PTSD that can develop in people who experience ongoing or long-term trauma or multiple traumas. This may include ...
U.S. President-elect Donald Trump says he wants to make Greenland a part of the United States, renewing an interest first expressed in 2019 when he offered to buy the sprawling Arctic island from ...
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. [1] Axogen products are designed to remedy peripheral nerve damage. [2] [3] [4] In 2013 the company raised $18 million in its initial public offering (IPO). [5] Axogen uses a cell graft technology AVANCE to mimic a human nerve.